FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 326:910-915 April 2, 1992 Number 14 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

BACKGROUND. Nephropathy may develop in patients with sickle cell disease. We determined the prevalence of proteinuria and renal insufficiency in a group of patients with sickle cell disease and investigated the renal pathologic changes and the effects of an angiotensin-converting-enzyme inhibitor (enalapril) on protein excretion in patients found to have nephropathy. METHODS. We prospectively screened 381 patients with sickle cell disease for the presence of proteinuria and renal insufficiency. Renal biopsy and measurements of glomerular filtration rate, effective renal plasma flow, and urinary protein excretion were performed in 10 patients with mild nephropathy before and after the administration of enalapril, and again two to three weeks after its discontinuation. RESULTS. Of the 381 patients with sickle cell disease, 26 (7 percent) had serum creatinine concentrations above the normal range and 101 (26 percent) had proteinuria of at least 1+. The renal lesions in the 10 patients who had biopsies consisted of glomerular enlargement and perihilar focal segmental glomerulosclerosis. The mean (+/- SD) glomerular area in these patients was 28.7 +/- 4.1 x 10(3) micron 2, as compared with 15.8 +/- 4.3 x 10(3) micron 2 in 10 control patients without renal disease who had died of trauma (P less than 0.0001). During the administration of enalapril, the mean 24-hour urinary protein excretion decreased 57 percent (range, 23 to 79 percent) below the base-line value (P less than 0.001), and it increased to 25 percent below the base-line value after enalapril was discontinued. The glomerular filtration rate and effective renal plasma flow did not change significantly. CONCLUSIONS. Approximately 25 percent of patients with sickle cell disease have proteinuria. Treatment with enalapril reduces the degree of proteinuria in these patients, suggesting that glomerular capillary hypertension may be a pathogenic factor in sickle cell nephropathy.

Source Information

Department of Medicine, University of North Carolina, Chapel Hill.

This article has been cited by other articles:

• Marsenic, O., Couloures, K. G., Wiley, J. M. (2008). Proteinuria in children with sickle cell disease. Nephrol Dial Transplant 23: 715-720 [Abstract] [Full Text]  
• Sebastiani, P., Nolan, V. G., Baldwin, C. T., Abad-Grau, M. M., Wang, L., Adewoye, A. H., McMahon, L. C., Farrer, L. A., Taylor, J. G. IV, Kato, G. J., Gladwin, M. T., Steinberg, M. H. (2007). A network model to predict the risk of death in sickle cell disease. Blood 110: 2727-2735 [Abstract] [Full Text]  
• Ntim, W. O., Upadhya, B., Cruz, J. (2007). Diastolic Dysfunction Is an Independent Risk Factor for Death in Patients With Sickle Cell Disease. J Am Coll Cardiol 50: 378-378 [Full Text]  
• Thompson, J., Reid, M., Hambleton, I., Serjeant, G. R. (2007). Albuminuria and Renal Function in Homozygous Sickle Cell Disease: Observations From a Cohort Study. Arch Intern Med 167: 701-708 [Abstract] [Full Text]  
• Guasch, A., Navarrete, J., Nass, K., Zayas, C. F. (2006). Glomerular Involvement in Adults with Sickle Cell Hemoglobinopathies: Prevalence and Clinical Correlates of Progressive Renal Failure. J. Am. Soc. Nephrol. 17: 2228-2235 [Abstract] [Full Text]  
• Tharaux, P.-L., Hagege, I., Placier, S., Vayssairat, M., Kanfer, A., Girot, R., Dussaule, J.-C. (2005). Urinary endothelin-1 as a marker of renal damage in sickle cell disease. Nephrol Dial Transplant 20: 2408-2413 [Abstract] [Full Text]  
• Hofmann, N., Waldherr, R., Schwenger, V. (2005). Is the sauna a common place for experiencing acute renal failure?. Nephrol Dial Transplant 20: 235-237 [Full Text]  
• Lottenberg, R., Hassell, K. L. (2005). An Evidence-Based Approach to the Treatment of Adults with Sickle Cell Disease. ASH Education Book 2005: 58-65 [Abstract] [Full Text]  
• ASLAN, M., THORNLEY-BROWN, D., FREEMAN, B. A. (2000). Reactive Species in Sickle Cell Disease. Ann. N. Y. Acad. Sci. 899: 375-391 [Abstract] [Full Text]  
• GUASCH, A., ZAYAS, C. F., ECKMAN, J. R., MURALIDHARAN, K., ZHANG, W., ELSAS, L. J. (1999). Evidence that Microdeletions in the {alpha} Globin Gene Protect Against the Development of Sickle Cell Glomerulopathy in Humans. J. Am. Soc. Nephrol. 10: 1014-1019 [Abstract] [Full Text]  
• SABORIO, P., SCHEINMAN, J. I. (1999). Sickle Cell Nephropathy. J. Am. Soc. Nephrol. 10: 187-192 [Full Text]  
• Lane, P. H., Tyler, L. D., Schmitz, P. G. (1998). Chronic administration of furosemide augments renal weight and glomerular capillary pressure in normal rats. Am. J. Physiol. Renal Physiol. 275: F230-F234 [Abstract] [Full Text]  
• Border, W. A., Noble, N. A. (1998). Interactions of Transforming Growth Factor-{beta} and Angiotensin II in Renal Fibrosis. Hypertension 31: 181-188 [Abstract] [Full Text]  
• Rodgers, G. P., Walker, E. C., Podgor, M. J., Platt, O. S. (1994). Mortality in Sickle Cell Disease. NEJM 331: 1022-1023 [Full Text]  
• Perrine, S. P., Ginder, G. D., Faller, D. V., Dover, G. H., Ikuta, T., Witkowska, H. E., Cai, S.-p., Vichinsky, E. P., Olivieri, N. F. (1993). A Short-Term Trial of Butyrate to Stimulate Fetal-Globin-Gene Expression in the {beta}-Globin Disorders. NEJM 328: 81-86 [Abstract] [Full Text]  
• (1992). UNRAVELING THE PATHOLOGY OF SICKLE-CELL NEPHROPATHY. JWatch General 1992: 4-4 [Full Text]